Dislipidemiya u patsienta s arterial'noy gipertenziey: kombinirovannaya terapiya gipolipidemicheskimi i antigipertenzivnymi lekarstvennymi sredstvami


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article describes the clinical experience of management of patients with high risk for cardiovascular complications. For medical correction of arterial hypertension, tactics of combined antihypertensive therapy with angiotensin-converting enzyme inhibitor fosinopril in the starting dose of 10 mg daily and thiazide diuretic indapamide at the starting dose of 1.5 mg per day was chosen. At the end of cycle of therapy, improvement of BP levels, biochemical tests and endothelial function was revealed. This clinical case demonstrates the possibility of drug correction of endothelial dysfunction, which can improve BP control in patients with high risk of cardiovascular disease in the outpatient settings.

Full Text

Restricted Access

References

  1. Павлова О.С. Современные возможности эффективной сердечно-сосудистой профилактики у пациентов с артериальной гипертензией и дислипидемией. Мед. новости. 2012;1:62-68.
  2. Kannel W.B. Fifty years of Framingham study contributions to understanding hypertension. J. Hum. Hypertens. 2000.;14:83-90.
  3. Tunstall-Pedoe H., Chen R., Kramarz P. Prevalence of individuals with both raised blood pressure and raised cholesterol in WHO MONICA Project population surveys 1989-97. Pharmacoepidemiol. Drug. Saf. -2004;13(Suppl 1):307-08.
  4. Johnson M.L., Pietz K., Battleman D.S., Beyth R.J. Prevalence of co-morbidity hypertension and dyslipidemia and associated cardiovascular disease. Am. J. Manag. Care. 2004;10:926-32.
  5. Stamler J., Wentworth D., Neaton D. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am. J. Med. 1986; 80:33-9.
  6. Williams R.R., Hopkins P.N., Hunt S.C., Wu L.L., Hasstedt S.J., et al. Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. Arch. Intern. Med. 1990;150: 582-88.
  7. Klahr S., Morrissey J.J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int. 2000;57(Suppl 75):7-14.
  8. Wolf G. The Renin-Angiotensin System and Progression of Renal Disease. J. Am. Soc. Nephrol. 2006;17(11):2985-91.
  9. Delcayre C., Swynghedauw B. Molecular mechanisms of myocardial remodelling. The role of aldosterone. J. Mol. Cell Cardiology. 2002;34:1577-84.
  10. Ross R. Atherosclerosis an inflammatory disease. N. Engl. J. Med. 1999;340:115-26.
  11. O'Donnell V.B. Free radicals and lipid signaling in endothelial cells. Antiox. Redox. Signal. 2003;5:195-203.
  12. Wolfrum S., Jensen K.S., Liao J.K. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol. 2003;23:729-36.
  13. Kaplan M., Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxi dants and serum paraoxonase. Clin. Chem. Lab. Med. 1999;37:777-87.
  14. Campese V.M., Bianchi S., Bigazzi R. Association between hyperlipidemia andmicroalbuminuria in essential hypertension. Kidney Int. 1999;56(Suppl 71):10-3.
  15. Grundy S.M., Cleeman J.I., Merz C.N., et al. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association Review. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2): 227-39.
  16. Guidelines for the Management of arterial hypertension, task force of the European Society of Hypertension and the European Society of Cardiology. J. Hypertens. 2007;6: 1105-87.
  17. Reappraisal of European guidelines on hyperetension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009;11:2121-58.
  18. Borghi C., Prandin G., Costa V., Bacchelli S., Degli D., Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 2000;35:549-55.
  19. Cifkova R., Nilsson P. Statins and Hypertension. European Society of Hypertension Scientific Newsletter. Hypertension Management. 2008;9:35.
  20. Wolfrum S., Jensen K., Liao J.K. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol. 2003;23:729-36.
  21. Ide H., Fujiuya S., Aanuma Y., Agishi Y. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin. Ther. 1990;12:410-20.
  22. Shige H., Dart A., Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis. 2001;155:245-50.
  23. Ferrier K.E., Muhlmann M.H., Baguet J.P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J. Am. Coll. Cardiol. 2002;39:1020-25.
  24. Strazzullo P., Kerry S.M., Barbato A., et al. Do statins reduce blood pressure: a meta-analysis of randomized, controlled trials. Hypertension. 2007;49(4):792-98.
  25. Morgado M., Rolo S., Macedo A.F., Castelo-Bran-co M. Association of statin therapy with blood pressure control in hypertensive hypercholesterolemic outpatients in clinical practice. J. Cardiovasc. Dis. Res. 2011;2(1):44-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies